307
Participants
Start Date
September 1, 2024
Primary Completion Date
October 30, 2027
Study Completion Date
April 30, 2028
Fluzoparib
Parp inhibitor
Dalpiciclib
CDK4/6 inhibitor
Fulvestrant/AI
Endocrine therapy
breast cancer institute of Fudan University Cancer Hospital, Shanghai
First Hospital of China Medical University
OTHER
Sun Yat-sen University
OTHER
Chongqing University Cancer Hospital
OTHER
Fujian Medical University Union Hospital
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Shanghai First Maternity and Infant Hospital
OTHER
Affiliated Hospital of Nantong University
OTHER
Peking University Cancer Hospital & Institute
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Liaoning Cancer Hospital & Institute
OTHER
Northern Jiangsu People's Hospital
OTHER
Shanghai 6th People's Hospital
OTHER
Zhimin Shao
OTHER